4 CONCLUSION
In conclusion, this article has given an overview of the effects of
sivelestat on ALI/ARDS or ARDS with coagulopathy, both of which are
frequently seen in patients with COVID-19. This selective NE inhibitor
has not been evaluated for its possible therapeutic effects against
SARS-CoV-2 infection and/or COVID-19. Nevertheless, based on its
promising beneficial effects in underlying complications of COVID-19,
sivelestat could be considered as a promising treatment for the
management of ALI/ARDS or coagulopathy in patients with COVID-19. In the
end, we think that testing the possible efficacy of this therapeutic
modality in this group of patients could help in developing new
strategies for combating COVID-19.